Background: Lung cancer is still the most lethal malignancy in the world, according to the report of Cancer Statistics in 2021. Platinum-based chemotherapy combined with immunotherapy is the first-line treatment in lung cancer patients. However, the 5-year survival rate is always affected by the adverse reactions and drug resistance caused by platinum-based chemotherapy. DNA damage and repair system is one of the important mechanisms that can affect the response to chemotherapy and clinical outcomes in lung cancer patients. Objective: The objective of this study is to find the relationship between the polymorphisms of DNA repair genes with the prognosis of platinum-based chemotherapy in lung cancer patients. Patients and Methods: We performed genotyping in 17 single nucleotide polymorphisms (SNPs) of Excision Repair Cross-Complementation group (ERCC) genes and X-ray Repair Cross-Complementing (XRCC) genes of 345 lung cancer patients via Sequenom MassARRAY. We used Cox proportional hazard models, state, and plink to analyze the associations between SNPs and the prognosis of lung cancer patients. Results: We found that the ERCC5 rs873601 was associated with the overall survival time in lung cancer patients treated with platinum-based chemotherapy (p = 0.031). There were some polymorphisms that were related to the prognosis in specific subgroups of lung cancer. Rs873601 showed a great influence on the prognosis of patients more than 55 years, Small Cell Lung Cancer (SCLC), and smoking patients. Rs2444933 was associated with prognosis in age less than 55 years, SCLC, metastasis, and stage III/IV/ED patients. Rs3740051 played an important role in the prognosis of SCLC and metastasis patients. Rs1869641 was involved in the prognosis of SCLC patients. Rs1051685 was related to the prognosis in non-metastasis patients. Conclusion: The ERCC5 rs873601 (G>A) was a valuable biomarker for predicting the prognosis in lung cancer patients treated with platinum-based chemotherapy.

Stretch bending is a widely used to form long parts with a definite cross-section shape. The forming path is an effective way to eliminate the defects such as springback, distortion when the material and the die shape are determined. In this study, the stretch bending path is represented by a curve function of bending angle and stretch length. To simplify the path optimization problem, the path is represented by 4 parameters, including a newly introduced parameter of total stretch. Based on the batch simulation results, it is found that the axial springback and cross section distortion are primarily controlled by total stretch, bending angle and pre-stretch proportion. When the total stretch is determined, the different distribution schemes for pre-stretch, bending stretch and post-stretch in total stretch have a similar effect on forming quality except the schemes with extremely large proportions of pre-stretch. In most cases, with the total stretch length in growth, the axial springback decreases dramatically at first and then stays constant while the section distortion continues to rise, indicating that the optimal forming path is around the elbow point in the relationship curve of total stretch and springback angle. The optimal path is verified by experiments. It is shown that for a workpiece with determined material and die shape, the optimal path to minimize axial rebound and section distortion simultaneously does exit and the study provide an effective way to obtain it.

The pressure bearing capability of a folded multi-port flat tube (MPFT), which has the advantage of retaining the corrosion property of corrosion resistant materials, was investigated in this study with both a burst pressure test and finite element simulation. Results show that the folded tube’s failure is mainly caused by the breaking of the inner ribs. Instead of detecting inner pressure, the bulging ratio, which is supposed to be small under service pressure, rises rapidly before failure. Therefore, it is suggested to use bulging ratio to visibly determine the working status of folded MPFTs. Based on FE simulations, the pressure bearing capability of the folded MPFT was improved by optimizing the relevant folding parameters. In addition, the influence of in-plane bending was also investigated. It is found that the folded MPFTs can still retain most of the pressure bearing capability after in-plane bending.

Background: Lung cancer is still the most lethal malignancy in the world from the report of Cancer Statistics in 2021. Platinum-based chemotherapy combined immunotherapy is the first-line treatment in lung cancer patients. However, the 5-year survival rate always affected by the adverse reaction and drug resistance caused by platinum-based chemotherapy. DNA damage and repair system is one of the important mechanisms which can affect the response to chemotherapy and clinical outcome in lung cancer patients. Objective: The objective of this study is to find the relationship between the polymorphisms of DNA repair genes with the prognosis in platinum-based chemotherapy in lung cancer patients. Patients and Methods: We performed genotyping in 17 single nucleotide polymorphisms (SNPs) of Excision Repair Cross-Complementation group (ERCC) genes and X-ray Repair Cross-Complementing (XRCC) genes of 345 lung cancer patients by Sequenom MassARRAY. We used Cox proportional hazard models, state and plink to analyze the associations between SNPs and the prognosis of lung cancer patients. Results: We found that the ERCC5 rs873601 was associated with the overall survival time in lung cancer patients treat by platinum-based chemotherapy (p=0.031*). We also discovered that the polymorphisms in rs873601 was significantly associated with the prognosis in age more than 55 years, Small Cell Lung Cancer (SCLC) and smoking patients, Long Intergenic Non-protein Coding RNA (PNKY) rs2444933 in age less than 55 years, SCLC, metastasis and stage III/IV/ED patients, Short Tau Inversion Recovery (STIR1) rs3740051 in SCLC and metastasis patients, PNKY rs1869641 in SCLC patients, XRCC5 rs1051685 in non-metastasis patients, respectively. Conclusion: The ERCC5 rs873601(G>A) maybe a valuable biomarker for predicting the prognosis in lung cancer patients treated with platinum-based chemotherapy. Statements and Declarations: The authors declare that they have no conflict of interest.